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.-\hstrad: CylOkine mR!"A patterns were analyzed in 11 post-trans-
plant lymphoprolilcrati,·e disorder (PTLD) spe~imens using qualitative 
ren.:rsc-transniptase polymerase chain reaction l RT-PCR). In each 
! ~aseK a pallern of IL2 .IP',",' . IL4-. ILIO - was seen. A similar 
pallern was obsen ed in a spleen sample from I patient with contempo-
raneous PTLD elsewhere. 
Semlljuantitati,e RT-PCR for cylOkine message was performed using 
R!\A from bronchoaheolar la\age (BAL) specimens obtained from :; 
patients with pulmonary PTLD. In both cases. IL4 message predomi-
nated. Reduction of message coincided with resolution of the tumors. 
The pattern differed from that seen in I patient with acute pulmonar~ 
reJection. in whi~h RT-PCR of BAL cells showed predominance of IL6 
and IFNy. 
We conclude that at least some PTLDs exist within a T-helper cell type 
2 (Th2l-like cytokine mi~roenyironmentK The presence of a similar 
mRNA pattern in an extratullloral specimen at the time of PTLD 
suggests that it may reflect a systemic phenomenon. Disappearance of 
this pattern folll)"ing PTLD resolution indicates Jls dynamic nature 
and IS ~onsistent with the h~ pothesis that specific cytokines contribute 
to the development of PTLDs. 
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Post-transplant Iymphoproliferative disorders 
(PTLD) comprise a range of lymphoid tumors 
divisible into several c\inicopa thological categories 
( I). Most PTLDs are of B ceil origin and contain 
the Epstein· Barr virus (EB\'). which is considered 
to be a major cofac10r for their dewlopment (2. 3). 
It has been estimated that between 3) and RMD~D" 
of all PTLDs may regress following reduction of 
iatrogenic immunosuppression (4. 5). and this is 
consistent with the concept that host immunity 
plays a role in controlling the growth of such 
lesions (6). Examination of the microenvironment 
of PTLDs may. therefore. help to define a) the 
milieu within which tumor growth occurs: and bl 
intratumoral changes that occur during the process 
of tumor regression. 
The present study analyzes PTLDs for expres-
sion of mRNAs encoding several cytokines that 
may directly or indirectly influence B lymphocyte 
growth. In addition. semiquantitative and longitu-
dinal evaluations of cytokine mR NAs from bron-
choalveolar lavage (BAL) specimens in patients 
with lung-based PTLDs were performed to detect 
changes following resolution of these tumors. 
Materials and methods 
Specimens 
Twelve tissue specimens from 7 patients with 
PTLD were obtained as byproducts of diagnostic 
or therapeutic procedures performed at the Uni-
versity of Pittsburgh Medical Center. Pittsburgh. 
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PA from May 1990 to February 199:2. Tissues were 
obtained with approval of the Institutional Review 
Board. Eleven of these specimens represented 
PTLD tumors and the twelfth specimen derived 
from a splenectomy performed on a patient with 
PTLD at a separate site. 
Two spleen specimens from transplant patients 
without evidence of PTLD were used as control 
tissues. Six reactive lymph nodes and one splenic 
specimen from nontransplant patients were also 
used as technical controls. 
Tissues were snap-frozen in liquid nitrogen-
cooled isopentane and stored at - 80°C until use. 
Fresh cells were obtained as byproducts of BAL 
in two additional patients with pulmonary PTLO. 
both at the times of tumor diagnosis and following 
tumor resolution. The clinical course of one of 
these patients has been reported previously (7). 
BALs were performed in a third lung transplant 
recipient without evidence of PTLO both at the 
time of allograft rejection and following resolution 
of rejection. 
Cytokine mRNA polymerase chain reaction 
Total RNA was extracted from frozen tissues or 
cells and eDNA synthesis was carried out as previ-
ously described (7). Polymerase chain reaction 
(PCR) primers for IL2. IL4. IL6. ILIO and IFNI 
were synthesized at the l.J niversity of Pittsburgh 
DNA facility. Commercial primers for EBY (Re-
search Genetics. Huntsville. AL) were also utilized. 
and primers detecting actin were used as positive 
controls for each specimen. 
Table '. PathOlogic features of stuDV oatlems 
EBV -negative H UT78 cells were obtained from 
the American Type Culture Collection (Rockville. 
MO) and were used as positive controls for IFNi'. 
IL:2 and ILIO. Phytohemagglutinin-stimulated pe-
ripheral blood mononuclear cells sened as positive 
controls for IL6 mRNA detection. A plasmid con-
taining the IL4 gene was' used as a positive control 
for IL4 primers. EBY -transformed cells were used 
to test the EBY primers. 
Qualitative PCR using cDNA from solid tissue 
samples was carried out for 30 cycles and the 
products visualized with ethidium bromide. 
BAL cell cDNA samples were analyzed for the 
expression of cytokine mRNA using a semi-quanti-
tati\:e reverse transcriptase-PCR (RT-PCR) with 
11P-deoxycytidine triphosphate-labelled oligo-
primers. quantitated on a Betagen radioanalytic 
scanner and the results were expressed as counts 
per min. ~-actin mRNA was measured as an inter-
nal control for each BAL specimen. The results are 
reported as the ratio of cytokine per actin mo~K-yK 
Results 
Clinicopathologic features of post-transplant 
Iymphoproliferative disordersg 
Clinicopathologic features of the study specimens 
are shown in Table I. Solid tissue samples were 
obtained from patients 1-7. and patients 8-10 
were the sources of BAL specimens. Two or more 
PTLOs were sampled in 3 patients. In one case 
(patient II. a pharyngeal lesion arose 5 months 
following resection of a PTLD that was connned 
to the allograft liver. Both tumors had the appear-
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PT LD oat lems 
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ance of a large cell non-Hodgkin's lymphoma 
(monomorphic PTLD) and both demonstrated 
identical rearrangements of the immunoglobulin 
heavy chain gene. In patients 2 and 3. synchronous 
and noncontiguous tumors were sampled. In one 
case (patient 2). the presence of two separate clonal 
proliferations was documented. 
PTLD was not further categorized in patients 8 
and 9. both of whom had pulmonary lesions. 
Treatment included reduction of immunosup-
pression and acyclovir in all cases. Patient 3 re-
quired allograft resection and patient 7 received 
subsequent chemotherapy. Patient 9 received addi-
tional therapy with '.X-interferon. 
PTLD resoh'ed in 5 patients (Nos. I. 4. 7-9) 
and the remaining 4 tumor patients (Nos. 2. 3. 5. 
6) expired with PTLD. Patient 10. included as a 
control. did not have PTLD at any lime during the 
post-transpbnt course. 
EBV status of PTLOs 
All II solid tissue PTLD specimens were positive 
for EBV by peR analysis (Table 2). Specimen 6. 
taken from uninvolved spleen in a PTLD patient. 
was negative for this target. A pulmonary biopsy 
from patient 9 was positive for EBV by in situ 
hybridization for Epstein - Barr early RNA 
(EBER). Insufficient tissue was available from pa-
tient 8 to perform this assay. 
Cytoklne mRNA profiles of PTLOs 
All 12 specimens from PTLD patients showed a 
similar qualitative cytokine mRNA profile of 
IL:! ~ . IFNy - . I L4 - . III 0 + (Table 2). Representa-
tive patterns of two separate tumors resected 5 
months apart from patient I are shown in Fig. 1. 
In this example. the first tumor represented a 
PTLD c~·tokines 
lymphomatous PTLD. which was localized to the 
allograft. The second tumor arose in the pharynx 
after a 5-month tumor-free inten·al. Pathologic 
evaluation of this case was previously reported and 
it was concluded that the second lesion represented 
a true recurrence of the primary tumor (8). 
In patient 6. splenectomy was performed at the 
time of acti\c PTLD. Although the spleen itself 
was not in\olved by tumor. it demonstrated a 
cytokine mRNA pratlle similar to that seen in 
PTLD specimens. I.!xcept for the absence of EBV. 
Two splenic specimens were obtained from 
transplant recipients at the time of acute rejection. 
Both specimens were negative for EBV. In one case 
the cytokine mRNA pattern was IL:! -. IFNy·. 
IL4+. ILlO- and in the other it was IU4-. 
fcky~K IL4-. ILIO-. A splenic specimen ob-
tained from 1 non transplant patient was associated 
with a pattern similar to that found in the PTLDs. 
except for the absence of EBV. Six lymph nodes 
from 5 nontransplant patients were also analyzed. 
All were EBV negative. In one case no cytokine 
mRNA was detected. in two cases only weak ex-
pression of ILl 0 mR N A was seen. and in one case 
ILIO positivity was coupled with weak expression 
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Fig. 1. Ethidium bromIde-stained gel electrophoreSIS of RT· 
PC'R reaction pr0ducts for cytokines. I A and I B refer to two 
separate specimens from patient I. These noncontiguous clonal 
PTLDs occurred :; months apart. Lane I: DNA size ladder: 
Lanes::! - 4: positive IL:! control and patient samples: Lanes 
5 -7: posni\e IL4 control and pallent samples: Lanes fy~ 10: 
positive IFNy control and patient samples: Lanes 11- 13: ILIO 
positive control and pallent samples: Lanes 14: R I. negative 
plasmid D!\A control. 
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Table 3. Semiquantitative cytoklne RT-PCR oerformed on BAL specimens. The results are expreSSed as the ratio at cytokine mRNA to ~-actln mRNA 
Specimen PTlD IL2 IFN;' 
8A + 0.05 0.01 
8B 0.04 <0.01 
9A 0.25 0.06 
98 001 0 
lOA <0.01 1.7 
lOB <0.01 0.3 
IL2. Interleukln 2: iFN'!. Interferon '!: IL4. Interieukln 4: 1L10. ,nteneukln 10. 
of IL2. A fifth example showed expression of all 
four cytokine mRNAs, and in the sixth case the 
pattern was IL2 + , IFNy +, IL4 -. ILID +. 
BAL cells from the 2 lung transplant recipients 
with biopsy-proven pulmonary PTLD revealed 
strong expression of IL4 mRNA when analyzed by 
semiquantitative RT-PCR (Table 3). Prominent 
ILID mRNA expression was also seen in one case 
(specimen 9A. Table -,) and was expressed to a 
lesser extent in the second case. In contrast to the 
results of qualitative analysis, some expression of 
IL2 and IFNy mRNA was observed in both of 
these patients. IL6 mRNA was also detected in 
both specimens. 
Decreased levels of all of the above cytokine 
mRNAs relative to actin mRNA were seen in BAL 
specimens taken from both of these patients at 
time of PTLD resolution. 
In contrast to this pattern, IL6 and IFN'( were 
the predominant cytokine mRNAs found during 
an acnte rejection episode in patient 10 (specimen 
lOA. Table 3). Relative val ues for these cytokines 
also decreased following successful treatment of 
rejection. 
No correlation between the original PTLD cy-
tokine profile and histology, c!onality, time inter-
val from transplant to tumor. tumor location or 
response to treatment could be inferred from this 
study. 
Discussion 
The results of this study suggest that many PTLDs 
exist within a T-helper cell type 2 (Th2)-1ike (9) 
cytokine environment. In all PTLD specimens ana-
lyzed by qualitative RT-PCR in this series, IL4 and 
ILIO mRNA were present and neither IL2 nor 
IFNi were found. This pattern was not seen in 
either of two splenic specimens obtained from 
transplant patients v.ithout PTLD, nor in any of 
six control lymph nodes resected from nontrans-
plant patients. The sole exception occurred in a 
spleen resected from I nontransplant patient. Use 
of a more sensitive semiquantitative technique 
again showed predominance of IL4 or IL4 to-
42 
IL4 IL6 1L10 
0.15 0.02 0.02 
0 <0.01 <0.01 
0.74 002 1.1.5 
0.09 0 2.6 
:) 1.6 0.08 
0 <0.01 <0.01 
get her with ILIO and this pattern ditTered from 
that seen in acute rejection, in which IFNi and IL6 
predominated. Although the sensitivity and specifi-
city of this assay are not yet known. this approach 
has been shown to be useful in the evaluation of 
pulmonary rejection. both in a rodent model and 
in clinical specimens (10. 11). In the case of BAL 
specimens. a variety of cell types. such as epithelial 
cells. macrophages and granulocytes. may con-
tribute to the final cytokine mRNA profile. Thus 
the longitudinal changes shown here mayor may 
not reflect the events that occur during regression 
of extra pulmonary PTLDs. 
The results of these intratumoral studies are 
compatible with those of Shapiro et aJ. (12) who 
were the first to describe a decrease in blood levels 
of :t-interferon and an increase in circulating IL4 
levels in a cohort of bone marrow transplant pa-
tients with PTlD. Immunosuppressed transplant 
recipients without PTLD also had elevated IL.+ 
levels relative to a nontransplant popUlation, but 
did not demonstrate a depression of :x-interferon as 
did the PTlD patients. Similarly. Burke et al. (13) 
demonstrated decreased serum IL2 in conjunction 
with a rise in serum IL4 in a patient with dissemi-
nated PTLD. The presence of a systemic Th2-like 
cytokine profile during PTLD is also suggested by 
the specimen from patient 6 in the current study. 
In this case. the patient had a PTLD that did not 
invohe the spleen. Nevertheless. a Th2-like cy-
tokine mRNA profile was identified in the test 
sample derived from this organ. This may be coin-
cidental. or it may ret'Iect a systemic Th2-like pat-
tern during PTLD as suggested by others (12. 131. 
The role of individual cytokines within PTLD 
remains speculative. For example. IL-+ may selec-
tively drive T cells toward a Th2 phenotype. in 
addition to having a stimulatory effect on B cells 
(14). It seems likely that either or both of these 
activities may contribute to PTLD development. 
but this has not yet been formally proven. 
ILiD is also known to suppress the Th I cytokine 
response (14). and the absence of detectable Thl-
associated cytokines IL2 or IFN'! in the solid 
PTLD specimens is consistent with this role. How-
e\er. ILIO may also be demonstrated locally in the 
context of acute cellular rejection. which is not 
associated with a Th2-predominant pattern (15. 
161. Th us. the demonstra tion of this cytokine alone 
does not predict the overall cytokine milieu. 
ILIO may also sen'e as an autocrine paracrine 
gr\.)\\ th factor for B-Iymphocytes. and one study 
showed this c1Tect using spontaneous Iymphoblas-
toid B cell lines deri\ed from the blood of a patient 
with PTLD (17L Ho\\ewr. Randha\\a et al. (18) 
failed to show growth stimulation l,f a PTLD-
deri\cd B cell line upon addition of recombinant 
ILIO. despite the fact that the cell line itself pro-
dw.:cd ILIO. Similarly. ILIO-stimulated B cell 
grll\\lh could not be demonstrated by Kanno et al. 
([9) in a separate study of a pyothorax-associated 
EBY-positi\'e B cell lymphoma from a nonim-
munosuppressed patient. 
Re\'ersal of the Th2 pattern coincident with 
PTLD resolution in 2 patients \\ith longitudinal 
sample analysis lends support to efforts designed 
to bring about a host antitumor response by use of 
immuIlllmodulatil1n. like the withdrawal of im-
m Utwsupprcssion \Jr administration of Th I-associ-
ated cytokines (20). such as :x-interferon (il. It is 
also concei\abk that the use of anti-cytokine anti-
bodies such as anti-IL4 and possibly anti-IL-IO 
antibodies ma~ alter the PTLD microenvironment 
and thus facilitate a cytotoxic host antitumor re-
sponse. Such approaches could concei\ably be 
combined with newer methods of adopti\e cellular 
immunotherapy EK~1-OPF in order to generate an 
enhanced anti-tumor response with a reduced risk 
of organ rejection. Toward this end. further de-
scription of PTL D-associated cytokines and an 
anal~ sis of the function of these cytokines within 
these tumors appear warranted. 
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